Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2025-12-29 00:00:00 ET · period of report 2025-12-22 · accession 0001831410-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2025-12-22 | OLMA | Harmon Cyrus | Dir | S - Sale | $28.53 | -2,881 | 741.3K | -0.4% | -$82.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-22 | S | D | 2,881 | $28.53 | 741,259 | D | — | — | (F1) The weighted average sale price for the transaction reported was $28.53, and the range of prices was between $28.50 and $28.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |